Back to search
FDAFDA · Food and drugs·Recall number Z-2383-2026

Description/REF: PACING/PSI KIT: 5 FR 2L/ASK-07155-MGU

Published June 24, 2026 · Recall initiated: April 21, 2026

Summary

FDA records medical device Class I recall Z-2383-2026, published June 24, 2026 and initiated April 21, 2026. Recalling firm: ARROW INTERNATIONAL, LLC; Status: Ongoing; Reported quantity: 95; Lot: REF(Material)/UDI-DI/Lot(Batch): ASK-07155-MGU/10801902210217/33F25C0798. Class I means a reasonable probability of serious adverse health consequences or death.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Lidocaine, Bupivacaine, and 0.9% sodium chloride, the subject of a supplier recall, were included into kits and sets. The supplier was found to have quality issues and limited reports of drug ineffectiveness, and if sterility of a water-based injectable product is compromised this could lead to serious or life-threatening injuries.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
ARROW INTERNATIONAL, LLC
Distributor
US Nationwide distribution including in the states of VA, NY, UT, SC, LA, MN, PA, AZ, CA, MI, OH, FL, CT, KS, IL, TX, WI, GA, NC, MD, OR, AK, NH, IA, ND, OK, NM, AL, MA, KY, WA, AR, CO, IN, ME, TN, WY, NJ, SD, MS, MO, MT, DE, ID, NE, WV, RI, VT, NV, HI, DC, PR.
Lot
REF(Material)/UDI-DI/Lot(Batch): ASK-07155-MGU/10801902210217/33F25C0798
Risk classification
Class I
Area (FDA)
device
Country
United States

Related recalls

Questions about this recall

Was Description/REF: PACING/PSI KIT: 5 FR 2L/ASK-07155-MGU recalled?

Yes. FDA published recall Z-2383-2026 on June 24, 2026. Reported hazard: Lidocaine, Bupivacaine, and 0.9% sodium chloride, the subject of a supplier recall, were included into kits and sets. The supplier was found to have quality issues and limited reports of drug ineffectiveness, and if sterility of a water-based injectable product is compromised this could lead to serious or life-threatening injuries.

What should I do if I have this product?

Voluntary: Firm initiated · Letter